Sawgrass Asset Management LLC Buys 43,598 Shares of Johnson & Johnson (NYSE:JNJ)

Sawgrass Asset Management LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 66.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 109,395 shares of the company’s stock after buying an additional 43,598 shares during the quarter. Johnson & Johnson accounts for 1.7% of Sawgrass Asset Management LLC’s investment portfolio, making the stock its 12th largest holding. Sawgrass Asset Management LLC’s holdings in Johnson & Johnson were worth $15,821,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of JNJ. AMF Tjanstepension AB raised its stake in shares of Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after purchasing an additional 52,997 shares during the period. Alpha Financial Partners LLC bought a new stake in Johnson & Johnson in the third quarter worth about $209,000. Wealth Group Ltd. purchased a new position in Johnson & Johnson in the third quarter valued at about $213,000. Creative Planning grew its position in shares of Johnson & Johnson by 4.3% during the 3rd quarter. Creative Planning now owns 988,403 shares of the company’s stock valued at $160,181,000 after acquiring an additional 41,082 shares during the period. Finally, Swedbank AB raised its holdings in shares of Johnson & Johnson by 5.3% in the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock worth $358,980,000 after purchasing an additional 111,570 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Raymond James lowered their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Wolfe Research started coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Guggenheim upped their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Finally, Barclays lifted their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Trading Down 0.7 %

Shares of JNJ stock opened at $156.20 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $376.08 billion, a price-to-earnings ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The stock’s 50-day moving average price is $147.87 and its 200-day moving average price is $156.00.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same period last year, the company posted $2.29 EPS. The business’s revenue was up 5.3% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.18%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.